Welcome to our dedicated page for Lexaria Bioscien SEC filings (Ticker: LEXXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexaria Bioscience Corp. filings document public-company governance and material-event reporting for a Nevada corporation developing DehydraTECH drug-delivery technology. The available 8-K disclosure records annual shareholder meeting results, including director elections, auditor appointment, and ratification of director actions.
The company’s regulatory record centers on governance mechanics, security-holder voting outcomes, corporate identity information, and formal reporting obligations tied to its public listing. These filings complement operating updates about Lexaria’s research, patent portfolio, and pharmaceutical drug-delivery programs.
Lexaria Bioscience Corp. reports lower revenue and a narrower loss while highlighting going concern risks. For the six months ended February 28, 2026, revenue fell to $20,000 from $357,923, reflecting the expiration of a key licensing contract and reduced B2B focus. Net loss attributable to shareholders improved to $3.0 million from $5.4 million as research and development spending decreased after completing a major GLP‑1 clinical trial.
Cash rose to $5.1 million with working capital of $5.6 million, largely driven by two equity financings that raised about $6.5 million in net proceeds. Despite this, accumulated deficit reached $66.5 million, and recurring losses and negative cash flows led management to state there is “substantial doubt” about the company’s ability to continue as a going concern over the next year. Management expects current cash to fund operations only through the first quarter of fiscal 2027 and plans to rely on additional equity or partnership funding.
Lexaria Bioscience Corp. reports lower revenue and a narrower loss while highlighting going concern risks. For the six months ended February 28, 2026, revenue fell to $20,000 from $357,923, reflecting the expiration of a key licensing contract and reduced B2B focus. Net loss attributable to shareholders improved to $3.0 million from $5.4 million as research and development spending decreased after completing a major GLP‑1 clinical trial.
Cash rose to $5.1 million with working capital of $5.6 million, largely driven by two equity financings that raised about $6.5 million in net proceeds. Despite this, accumulated deficit reached $66.5 million, and recurring losses and negative cash flows led management to state there is “substantial doubt” about the company’s ability to continue as a going concern over the next year. Management expects current cash to fund operations only through the first quarter of fiscal 2027 and plans to rely on additional equity or partnership funding.
Lexaria Bioscience Corp. reported the results of its annual shareholder meeting held on January 27, 2026. A total of 8,380,389 shares, or 37.71% of issued share capital as of December 1, 2025, were represented in person or by proxy.
Shareholders elected all seven director nominees, with approval levels ranging from 73.6% to 96.4%. They also approved the appointment of Malone Bailey LLP as auditors, with 97.0% of votes cast in favor.
In addition, shareholders voted to ratify the lawful actions of the directors for the past year, with 90.0% approval, signaling broad support for the company’s current leadership and governance decisions.